Buckley Kohlhauff
Chief Tech/Sci/R&D Officer bei NURIX THERAPEUTICS, INC.
Profil
Buckley Kohlhauff is currently the Senior Vice President-Information Technology at Nurix Therapeutics, Inc. Prior to this, he held the position of Senior Director-Information Systems at Lexicon Pharmaceuticals, Inc. and Senior Director-Information Technology at Five Prime Therapeutics, Inc. He obtained his undergraduate degree from Carnegie Mellon University.
Aktive Positionen von Buckley Kohlhauff
| Unternehmen | Position | Beginn |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.09.2021 |
Ehemalige bekannte Positionen von Buckley Kohlhauff
| Unternehmen | Position | Ende |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| FIVE PRIME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Buckley Kohlhauff
| Carnegie Mellon University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
